#PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA
1	1	0	23	PIPERACILLIN/TAZOBACTAM
1	2	24	26	IN
1	3	27	37	CONTINUOUS
1	4	38	46	INFUSION
1	5	47	53	VERSUS
1	6	54	66	INTERMITTENT
1	7	67	75	INFUSION
1	8	76	78	IN
1	9	79	87	CHILDREN
1	10	88	92	WITH
1	11	93	100	FEBRILE
1	12	101	112	NEUTROPENIA
#BACKGROUND: Febrile neutropenia (FN) is a common complication in children who receive chemotherapy for cancer.
2	1	113	123	BACKGROUND
2	2	123	124	:
2	3	125	132	Febrile
2	4	133	144	neutropenia
2	5	145	146	(
2	6	146	148	FN
2	7	148	149	)
2	8	150	152	is
2	9	153	154	a
2	10	155	161	common
2	11	162	174	complication
2	12	175	177	in
2	13	178	186	children
2	14	187	190	who
2	15	191	198	receive
2	16	199	211	chemotherapy
2	17	212	215	for
2	18	216	222	cancer
2	19	222	223	.
#OBJECTIVE: The objective of this study was to evaluate the clinical efficacy of the continuous versus intermittent infusion of piperacillin/tazobactam (TZP) in febrile neutropenic pediatric patients.
3	1	335	344	OBJECTIVE
3	2	344	345	:
3	3	346	349	The
3	4	350	359	objective
3	5	360	362	of
3	6	363	367	this
3	7	368	373	study
3	8	374	377	was
3	9	378	380	to
3	10	381	389	evaluate
3	11	390	393	the
3	12	394	402	clinical
3	13	403	411	efficacy
3	14	412	414	of
3	15	415	418	the
3	16	419	429	continuous
3	17	430	436	versus
3	18	437	449	intermittent
3	19	450	458	infusion
3	20	459	461	of
3	21	462	485	piperacillin/tazobactam
3	22	486	487	(
3	23	487	490	TZP
3	24	490	491	)
3	25	492	494	in
3	26	495	502	febrile
3	27	503	514	neutropenic
3	28	515	524	pediatric
3	29	525	533	patients
3	30	533	534	.
#METHODS: This is a non-blinded randomized controlled clinical trial.
4	1	735	742	METHODS
4	2	742	743	:
4	3	744	748	This
4	4	749	751	is
4	5	752	753	a
4	6	754	765	non-blinded
4	7	766	776	randomized
4	8	777	787	controlled
4	9	788	796	clinical
4	10	797	802	trial
4	11	802	803	.
#Eligible group consisted of hemato-oncological patients with FN who were candidates to receive TZP.
5	1	873	881	Eligible
5	2	882	887	group
5	3	888	897	consisted
5	4	898	900	of
5	5	901	919	hemato-oncological
5	6	920	928	patients
5	7	929	933	with
5	8	934	936	FN
5	9	937	940	who
5	10	941	945	were
5	11	946	956	candidates
5	12	957	959	to
5	13	960	967	receive
5	14	968	971	TZP
5	15	971	972	.
#Patients were randomized to one of two groups: Group 1 received antibiotic treatment through intravenous intermittent infusion of TZP 300 mg/kg/day based on piperacillin, divided into four doses, not exceeding 16 g/day; Group 2 received an initial TZP loading dose of 75 mg/kg infusion over 30 min, and then a continuous infusion of TZP 300 mg/kg/day through central line with pump over 24 h. RESULTS: There were 176 episodes that could be assessed, 100 in Group 1 and 76 in Group 2.
6	1	1073	1081	Patients
6	2	1082	1086	were
6	3	1087	1097	randomized
6	4	1098	1100	to
6	5	1101	1104	one
6	6	1105	1107	of
6	7	1108	1111	two
6	8	1112	1118	groups
6	9	1118	1119	:
6	10	1120	1125	Group
6	11	1126	1127	1
6	12	1128	1136	received
6	13	1137	1147	antibiotic
6	14	1148	1157	treatment
6	15	1158	1165	through
6	16	1166	1177	intravenous
6	17	1178	1190	intermittent
6	18	1191	1199	infusion
6	19	1200	1202	of
6	20	1203	1206	TZP
6	21	1207	1210	300
6	22	1211	1220	mg/kg/day
6	23	1221	1226	based
6	24	1227	1229	on
6	25	1230	1242	piperacillin
6	26	1242	1243	,
6	27	1244	1251	divided
6	28	1252	1256	into
6	29	1257	1261	four
6	30	1262	1267	doses
6	31	1267	1268	,
6	32	1269	1272	not
6	33	1273	1282	exceeding
6	34	1283	1285	16
6	35	1286	1291	g/day
6	36	1291	1292	;
6	37	1293	1298	Group
6	38	1299	1300	2
6	39	1301	1309	received
6	40	1310	1312	an
6	41	1313	1320	initial
6	42	1321	1324	TZP
6	43	1325	1332	loading
6	44	1333	1337	dose
6	45	1338	1340	of
6	46	1341	1343	75
6	47	1344	1349	mg/kg
6	48	1350	1358	infusion
6	49	1359	1363	over
6	50	1364	1366	30
6	51	1367	1370	min
6	52	1370	1371	,
6	53	1372	1375	and
6	54	1376	1380	then
6	55	1381	1382	a
6	56	1383	1393	continuous
6	57	1394	1402	infusion
6	58	1403	1405	of
6	59	1406	1409	TZP
6	60	1410	1413	300
6	61	1414	1423	mg/kg/day
6	62	1424	1431	through
6	63	1432	1439	central
6	64	1440	1444	line
6	65	1445	1449	with
6	66	1450	1454	pump
6	67	1455	1459	over
6	68	1460	1462	24
6	69	1463	1465	h.
6	70	1466	1473	RESULTS
6	71	1473	1474	:
6	72	1475	1480	There
6	73	1481	1485	were
6	74	1486	1489	176
6	75	1490	1498	episodes
6	76	1499	1503	that
6	77	1504	1509	could
6	78	1510	1512	be
6	79	1513	1521	assessed
6	80	1521	1522	,
6	81	1523	1526	100
6	82	1527	1529	in
6	83	1530	1535	Group
6	84	1536	1537	1
6	85	1538	1541	and
6	86	1542	1544	76
6	87	1545	1547	in
6	88	1548	1553	Group
6	89	1554	1555	2
6	90	1555	1556	.
#There was no statistically significant difference in treatment failure in the experimental group (continuous infusion) compared with the intermittent group, 21% versus 13% (p = 0.15).
7	1	2041	2046	There
7	2	2047	2050	was
7	3	2051	2053	no
7	4	2054	2067	statistically
7	5	2068	2079	significant
7	6	2080	2090	difference
7	7	2091	2093	in
7	8	2094	2103	treatment
7	9	2104	2111	failure
7	10	2112	2114	in
7	11	2115	2118	the
7	12	2119	2131	experimental
7	13	2132	2137	group
7	14	2138	2139	(
7	15	2139	2149	continuous
7	16	2150	2158	infusion
7	17	2158	2159	)
7	18	2160	2168	compared
7	19	2169	2173	with
7	20	2174	2177	the
7	21	2178	2190	intermittent
7	22	2191	2196	group
7	23	2196	2197	,
7	24	2198	2200	21
7	25	2200	2201	%
7	26	2202	2208	versus
7	27	2209	2211	13
7	28	2211	2212	%
7	29	2213	2214	(
7	30	2214	2215	p
7	31	2216	2217	=
7	32	2218	2222	0.15
7	33	2222	2223	)
7	34	2223	2224	.
#The increase in the absolute risk reduction was 0.08% (95% confidence interval 0.12-0.30), and the number needed to treat was 12.4.
8	1	2409	2412	The
8	2	2413	2421	increase
8	3	2422	2424	in
8	4	2425	2428	the
8	5	2429	2437	absolute
8	6	2438	2442	risk
8	7	2443	2452	reduction
8	8	2453	2456	was
8	9	2457	2461	0.08
8	10	2461	2462	%
8	11	2463	2464	(
8	12	2464	2466	95
8	13	2466	2467	%
8	14	2468	2478	confidence
8	15	2479	2487	interval
8	16	2488	2492	0.12
8	17	2492	2493	-
8	18	2493	2497	0.30
8	19	2497	2498	)
8	20	2498	2499	,
8	21	2500	2503	and
8	22	2504	2507	the
8	23	2508	2514	number
8	24	2515	2521	needed
8	25	2522	2524	to
8	26	2525	2530	treat
8	27	2531	2534	was
8	28	2535	2539	12.4
8	29	2539	2540	.
#One patient in each group died.
9	1	2673	2676	One
9	2	2677	2684	patient
9	3	2685	2687	in
9	4	2688	2692	each
9	5	2693	2698	group
9	6	2699	2703	died
9	7	2703	2704	.
#CONCLUSIONS: There were no differences in fever resolution, clinical cure rate, or mortality when comparing the continuous with the intermittent TZP infusion.
10	1	2737	2748	CONCLUSIONS
10	2	2748	2749	:
10	3	2750	2755	There
10	4	2756	2760	were
10	5	2761	2763	no
10	6	2764	2775	differences
10	7	2776	2778	in
10	8	2779	2784	fever
10	9	2785	2795	resolution
10	10	2795	2796	,
10	11	2797	2805	clinical
10	12	2806	2810	cure
10	13	2811	2815	rate
10	14	2815	2816	,
10	15	2817	2819	or
10	16	2820	2829	mortality
10	17	2830	2834	when
10	18	2835	2844	comparing
10	19	2845	2848	the
10	20	2849	2859	continuous
10	21	2860	2864	with
10	22	2865	2868	the
10	23	2869	2881	intermittent
10	24	2882	2885	TZP
10	25	2886	2894	infusion
10	26	2894	2895	.
